rss
Br J Ophthalmol 2005;89:764-769 doi:10.1136/bjo.2004.062547
  • Perspective

Spare the rod and spoil the eye

  1. G B Arden1,
  2. R L Sidman2,
  3. W Arap3,
  4. R O Schlingemann4
  1. 1Henry Wellcome Laboratories, Applied Vision Research Centre, Department of Optometry and Visual Science, City University, London EC1V 0HB, UK
  2. 2Neurology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
  3. 3The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
  4. 4Medical Retina Unit, Department of Ophthalmology, Academic Medical Center, PO Box 22700, 1100 DE Amsterdam, Netherlands
  1. Correspondence to: G B Arden Henry Wellcome Laboratories, Applied Vision Research Centre, Department of Optometry and Visual Science, City University, Northampton Square, London EC1V 0HB, UK; g.ardencity.ac.uk
  • Accepted 14 January 2005

Abstract

This review presents a new unified view of the pathogenesis of three common causes of acquired retinal degenerative disease—diabetic retinopathy, age related macular degeneration, and retinopathy of prematurity. In these three conditions, angiogenesis has a predominant role in the development of sight threatening pathology. Angiogenesis is controlled by among other factors the expression of vascular endothelial growth factor (VEGF), which in turn is regulated by absolute and relative lack of oxygen. The severe pathological manifestations of these three conditions are not part of a general underlying disease process because they are peculiar to the eye, and the profound hypoxia that develops in normal retina during dark adaptation (rod driven hypoxia) is an adequate and elegant additional factor to explain their pathogenesis. A large number of experimental reports support this conclusion, although rod driven anoxia is not generally considered as a causal factor in ocular disease. However, the hypothesis can be critically tested, and also suggests novel methods of treatment and prevention of these conditions that may be simpler and more inexpensive than current therapies and that have a smaller potential for adverse effects.

Footnotes

    This Article

    Services

    1. Request permissions

    Responses

    1. Submit a response
    2. No responses published

    Social bookmarking

    Register for free content


    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.